参考文献/References:
［1］YURDAKK M. Fetal and neonatal effects of anticoagulants used in pregnancy: a review ［J］. The Turkish Journal of Pediatrics, 2012, 54(3): 207-215.
［2］BRANCH D W, GIBSON M, SILVER R M. Clinical practice. Recurrent miscarriage ［J］. The New England Journal of Medicine, 2010, 363(18): 1740-1747.
［3］WEITZ J. Low molecular weight heparins［J］. Reactions Weekly, 2006, 1132(1): 16.
［4］NELSON S M, GREER I A. The potential role of heparin in assisted conception［J］. Human Reproduction Update, 2008, 14(6): 623-645.
［5］BENNETT S A, BAGOT C N, ARYA R. Pregnancy loss and thrombophilia: the elusive link［J］. British Journal of Haematology, 2012, 157(5): 529-542.
［6］林其德，苏小玲．抗磷脂抗体相关性复发性流产的诊治 ［J］．中国实用妇科与产科杂志，2013，29（2）：106-108．
［7］FRANKLIN R D, KUTTEH W H. Effects of unfractionated and low molecular weight heparin on antiphospholipid antibody binding in vitro ［J］. Obstetrics and Gynecology, 2003, 101(3): 455-462.
［8］XIE Hongxiang, ZHOU Hong, WANG Haibo, et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways［J］. Molecular Immunology, 2013, 53(3): 246-254.
［9］CHEN Ying, WU Xiao-xia, TAN Jian-ping, et al. Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester［J］. Fertility and Sterility, 2012, 97(3): 764-770.
［10］D'IPPOLITO S, DI NICUOLO F, MARANA R, et al. Emerging nonanticoagulant role of low molecular weight heparins on extravillous trophoblast functions and on heparin binding-epidermal growth factor and cystein-rich angiogenic inducer 61 expression ［J］. Fertility and Sterility, 2012, 98(4): 1028-1036.e1.
［11］OZBILGIN K, KARACA F, TURAN A, et al. The higher heparin-binding epidermal growth factor (HB-EGF) in missed abortion［J］. Taiwanese Journal of Obstetrics & Gynecology, 2015, 54(1): 13-18.
［12］NOBLE L S, KUTTEH W H, LASHEY N, et al. Antiphospholipid antibodies associated with recurrent pregnancy loss: prospective, multicenter, controlled pilot study comparing treatment with low-molecular-weight heparin versus unfractionated heparin ［J］. Fertility and Sterility, 2005, 83(3): 684-690.
［13］FAWAD S. Role of anti-thrombotic therapy for recurrent pregnancy loss due to anti-phospholipid syndrome ［J］. Journal of Ayub Medical College, Abbottabad : JAMC, 2012, 22(3): 197-200.
［14］ALALAF S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome ［J］. Archives of Gynecology and Obstetrics, 2012, 285(3): 641-647.
［15］EMPSON M B, LASSERE M, CRAIG J C, et al. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant［J］. The Cochrane Database of Systematic Reviews, 2005, 18(2): CD002859.
［16］FOUDA U M, SAYED A M, ABDOU A M, et al. Enoxaparin versus unfractionated heparin in the management of recurrent abortion secondary to antiphospholipid syndrome［J］. International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics, 2011, 112(3): 211-215.
［17］BULLETIN A P. 118:antiphospholipid syndrome［J］. Obstetrics and Gynecology, 2011, 117(1): 192-199.
［18］MOUSA H A, ALFIREVIC1 Z. Do placental lesions reflect thrombophilia state in women with adverse pregnancy outcome?［J］. Human Reproduction (Oxford, England), 2000, 15(8): 1830-1833.
［19］NELEN W L, BLOM H J, STEEGERS E A, et al. Hyperhomocysteinemia and recurrent early pregnancy loss:a meta analysis［J］. Fertility and Sterility, 2000, 74(6): 1196-1199.
［20］KRABBENDAM I, FRANX A, BOTS M L, et al. Thrombophilias and recurrent pregnancy loss: a critical appraisal of the literature［J］. European Journal of Obstetrics & Gynecology and Reproductive Biology, 2005, 118(2): 143-153.
［21］CHECK J H. The use of heparin for preventing miscarriage ［J］. American Journal of Reproductive Immunology (New York, N.Y.:1989), 2012, 67(4): 326-333.
［22］ARACIC N, ROJE D, DRMIC HOFMAN I, et al. Low molecular weight heparin treatment and impact of inherited thrombophilia type in pregnancies with previous adverse outcome［J］. The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2015, 28(3): 306-310.
［23］ARACIC N, ROJE D, JAKUS I A, et al. The impact of inherited thrombophilia types and low molecular weight heparin treatment on pregnancy complications in women with previous adverse outcome［J］. Yonsei Medical Journal, 2016, 57(5): 1230-1235.
［24］KARADAG C, YOLDEMIR T, KARADAG S D, et al. Obstetric outcomes of recurrent pregnancy loss patients diagnosed with inherited thrombophilia［J］. Irish Journal of Medical Science, 2017,186(3):707-713.
［25］AREIA A L, FONSECA E, AREIA M, et al. Low-molecular-weight heparin plus aspirin versus aspirin alone in pregnant women with hereditary thrombophilia to improve live birth rate: meta-analysis of randomized controlled trials［J］. Archives of Gynecology and Obstetrics, 2016, 293(1): 81-86.
［26］DE JONG P G, QUENBY S, BLOEMENKAMP K W, et al. ALIFE2 study: low-molecular-weight heparin for women with recurrent miscarriage and inherited thrombophilia——study protocol for a randomized controlled trial［J］. Trials, 2015, 16: 208.
［27］BRUSILOVSKY M, CORDOBA M, ROSENTAL B, et al. Genome-wide siRNA screen reveals a new cellular partner of NK cell receptor KIR2DL4: heparan sulfate directly modulates KIR2DL4-mediated responses［J］. Journal of Immunology (Baltimore, Md. : 1950), 2013, 191(10): 5256-5267.
［28］FLUHR H, SPRATTE J, EHRHARDT J, et al. Heparin and low-molecular-weight heparins modulate the decidualization of human endometrial stromal cells ［J］. Fertility and Sterility, 2010, 93(8): 2581-2587.
［29］LULEY L, SCHUMACHER A, MULLA M J, et al. Low molecular weight heparin modulates maternal immune response in pregnant women and mice with thrombophilia［J］. American Journal of Reproductive Immunology (New York, N.Y. : 1989), 2015, 73(5): 417-427.
［30］SHOMER E, KATZENELL S, ZIPORI Y, et al. Microvesicles of pregnant women receiving low molecular weight heparin improve trophoblast function ［J］. Thrombosis Research, 2016, 137: 141-147.
［31］YUKSEL H, KAYATAS S, BOZA A T, et al. Low molecular weight heparin use in unexplained recurrent miscarriage［J］. Pakistan Journal of Medical Sciences, 2015, 30(6): 1232-1237.
［32］SHAABAN O M, ABBAS A M, ZAHRAN K M, et al. Low-Molecular-Weight heparin for the treatment of unexplained recurrent miscarriage with negative antiphospholipid antibodies［J］. Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis, 2017,23(6):567-572.
［33］SESHADRI S, SUNKARA S K, KHALAF Y, et al. Effect of heparin on the outcome of IVF treatment: a systematic review and meta-analysis ［J］. Reproductive BioMedicine Online, 2012, 25(6): 572-584.
［34］SCHLEUSSNER E, KAMIN G, SELIGER G, et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicenter trial with a minimization randomization scheme［J］. Annals of Internal Medicine, 2015, 162(9): 601-609.
［35］CHECK J H. The use of heparin for preventing miscarriage ［J］. American Journal of Reproductive Immunology (New York, N.Y. : 1989), 2012, 67(4): 326-333.
［36］GALARZA-MALDONADO C, KOURILOVITCH M R, PREZ-FERNNDEZ O M, et al. Obstetric antiphospholipid syndrome［J］. Autoimmunity Reviews, 2012, 11(4): 288-295.
［37］MT1 D S. Khalid S,christos PJ.outcomes in women receiving low-molecular-weight heparin during pregnancy［J］. Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis, 2012, 23(8): 751-755.
相似文献/References:
[1]阚滨,肖美霞.妊娠合并血小板减少症65例临床分析[J].中国计划生育和妇产科,2009,(05):0.
KAN Bin,XIAO Mei-xia The department of gynaecology and obstetrics,Shengli hospital of Rugao city,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2009,(10):0.
[2]廖治,杨业洲.多发性硬化和妊娠[J].中国计划生育和妇产科,2009,(05):0.
[3]周萍,李秀美,江彩虹,等.妊娠合并卵巢肿瘤98例临床分析[J].中国计划生育和妇产科,2010,(02):0.
[4]莫丽芳.剖宫产手术中行子宫肌瘤剔除术体会[J].中国计划生育和妇产科,2010,(04):0.
MO Li-fang Shilong Peoples hospital of Dongguan city,Dongguan Guangdong,China.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(10):0.
[5]何博.妊娠合并先天性心脏病的诊治研究进展[J].中国计划生育和妇产科,2010,(04):0.
[6]韩雪玲.妊娠期合并尖锐湿疣200例治疗方法比较[J].中国计划生育和妇产科,2011,(04):0.
HAN Xue-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(10):0.
[7]张帆.孕妇哮喘及其安全监护[J].中国计划生育和妇产科,2011,(05):0.
ZHANG Fan Chinese Medical Doctor Association in Beijing,Beijing 000,P.R.China.[J].Chinese Journal of Family Planning & Gynecotokology,2011,(10):0.
[8]朱林,车兰芬.不同剂量米非司酮用于妊娠10～14周流产的临床观察[J].中国计划生育和妇产科,2012,(04):0.
ZHU Lin,CHE Lan-fen.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(10):0.
[9]韦冰,车小群,许丽华,等.血清CA125在评估卵巢子宫内膜异位囊肿的分期及术后妊娠情况中的价值[J].中国计划生育和妇产科,2012,(06):0.
WEI Bing*,CHE Xiao-qun,XU Li-hua Center of reproductive medicine,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(10):0.
[10]孙国娟.不同剂量米非司酮用于妊娠8～10周流产的临床观察[J].中国计划生育和妇产科,2013,(05):0.
SUN Guo-juan,[J].Chinese Journal of Family Planning & Gynecotokology,2013,(10):0.